2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2875

Anti-TNF Therapy Is Not Associated with an Increase in Neoplasias in Patients with Spondyloarthritis (SpA): Results from the GISEA Registry
Abstract Number: 2851

Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Abstract Number: 2468

Antibodies to Histocompatibility Antigens in Juvenile Systemic Lupus Erythematosus Patients
Abstract Number: 2057

Antibodies to Infliximab in Remicade-Treated Rheumatic Patients Show Identical Reactivity Towards Biosimilars
Abstract Number: 534

Antibodies to Malondialdehyde-Acetaldehyde Adducts Are Highly Expressed in Rheumatoid Arthritis Synovial Fluid
Abstract Number: 2551

Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen: a Model of Human Disease Response
Abstract Number: 1851

Antibody Against Ribonuclease-H Is a Novel Autoantibody Specifically Recognized in Systemic Lupus Erhythematosus
Abstract Number: 3083

Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Abstract Number: 811

Antibody Response to Periodontogenic Bacterium Aggregatibacter Actinomycetemcomitans and Lupus
Abstract Number: 518

Antibody Responses to Citrullinated Porphyromonas Gingivalis Peptidylarginine Deiminase: Associations with Disease Risk Factors and Severity in Rheumatoid Arthritis
Abstract Number: 483

Antibody to Malondialdehyde-Acetaldehyde (MAA) Adducts Serve As Biomarkers of Treatment Response in Rheumatoid Arthritis
Abstract Number: 520

Antibody to Porphyromonas Gingivalis in Pre-Clinical Rheumatoid Arthritis
Abstract Number: 2194

Anticoagulation and Longterm Outcomes in Patients with Renal Artery Stenosis and Antiphospholipid Syndrome
Abstract Number: 864

Anticytokine Autoantibody Profiling in Five Types of Systemic Vasculitis
Abstract Number: 2188

Antiphospholipid Antibodies and the Risk of Damage Accrual in Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].